MCID: MCL006
MIFTS: 55

Macular Retinal Edema

Categories: Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Macular Retinal Edema

MalaCards integrated aliases for Macular Retinal Edema:

Name: Macular Retinal Edema 12 15 71
Macular Edema 12 36 54 15
Macular Edema, Cystoid 71
Macular Retinal Oedema 12
Macular Oedema 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4449
KEGG 36 H01651
MeSH 43 D008269
NCIt 49 C35468
SNOMED-CT 67 37231002
UMLS 71 C0024440 C0271051

Summaries for Macular Retinal Edema

KEGG : 36 Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents.

MalaCards based summary : Macular Retinal Edema, also known as macular edema, is related to diabetic macular edema and vitreoretinopathy, neovascular inflammatory, and has symptoms including edema and peau d'orange. An important gene associated with Macular Retinal Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Acetazolamide and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and cellular

Related Diseases for Macular Retinal Edema

Diseases related to Macular Retinal Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 846)
# Related Disease Score Top Affiliating Genes
1 diabetic macular edema 34.0 VEGFB VEGFA PGF IL6 ICAM1 FLT1
2 vitreoretinopathy, neovascular inflammatory 33.1 VEGFA CRYAA CCL2
3 central retinal vein occlusion 32.5 VEGFA PGF IL6
4 macular dystrophy, dominant cystoid 32.4 VEGFA MRAP KCNMA1 CRYAA CRB1 ACE
5 vitreous detachment 32.0 VEGFB VEGFA KCNMA1
6 retinal vein occlusion 31.8 VEGFA TNF KDR IL6 CXCL8 CCL2
7 retinal detachment 31.7 VEGFA TNF IL6 CXCL8 CCL2
8 macular holes 31.7 VEGFA KCNMA1 CRYAA CCL2
9 uveitis 31.7 TNF IL6 ICAM1 CXCL8 CRYAA CCL2
10 retinitis pigmentosa 31.6 VEGFA TNF MRAP KCNMA1 INS IL6
11 intermediate uveitis 31.6 TNF MRAP IL6
12 neuroretinitis 31.6 MRAP ACE
13 posterior uveitis 31.6 TNF MRAP IL6
14 retinal ischemia 31.6 VEGFA TNF ICAM1 CRYAA
15 microvascular complications of diabetes 5 31.5 VEGFA PGF KDR INS ICAM1 FLT1
16 microvascular complications of diabetes 1 31.5 VEGFA INS ICAM1 FLT1 CXCL8 CCL2
17 panuveitis 31.4 TNF MRAP IL6 ACE
18 vasculitis 31.2 TNF IL6 ICAM1 CCL2
19 scotoma 31.2 VEGFA KCNMA1 CRB1
20 lipid metabolism disorder 31.2 INS IL6 CCL2 ACE
21 iridocyclitis 31.2 VEGFA TNF MRAP IL6 ACE
22 cataract 31.1 VEGFA TNF INS IL6 ICAM1 CXCL8
23 branch retinal artery occlusion 31.1 VEGFA FANCG CRYAA
24 coats disease 31.1 VEGFA KDR CRB1
25 microvascular complications of diabetes 3 31.0 INS ALB ACE
26 central retinal artery occlusion 31.0 VEGFA FANCG CRYAA
27 retinal vasculitis 31.0 TNF MRAP CCL2 ACE
28 kuhnt-junius degeneration 31.0 VEGFB VEGFA PGF KDR FLT1 CRYAA
29 iritis 31.0 TNF MRAP IL6 ACE
30 arteriovenous malformation 30.9 VEGFA TNF IL6
31 acquired immunodeficiency syndrome 30.9 TNF IL6 ICAM1 ALB
32 optic neuritis 30.9 VEGFA TNF IL6 CXCL8
33 poems syndrome 30.9 VEGFA TNF IL6
34 optic nerve disease 30.8 VEGFA TNF IL6 CRYAA ALB ACE
35 ocular tuberculosis 30.8 MRAP ACE
36 neuritis 30.8 TNF IL6 CXCL8 CCL2
37 keratopathy 30.8 TNF ICAM1 CXCL8
38 eales disease 30.8 VEGFA TNF IL6
39 scleritis 30.8 TNF MRAP CCL2
40 diabetic cataract 30.8 VEGFA INS CRYAA
41 sarcoidosis 1 30.8 TNF MRAP ICAM1 CCL2 ACE
42 juvenile rheumatoid arthritis 30.8 TNF IL6 CXCL8 CCL2 ALB
43 relapsing-remitting multiple sclerosis 30.7 TNF IL6 ICAM1 CXCL8 CCL2
44 severe nonproliferative diabetic retinopathy 30.7 VEGFA PGF INS ICAM1 CCL2 ALB
45 chickenpox 30.6 TNF IL6 ALB
46 keratitis, hereditary 30.6 VEGFA TNF IL6 CRYAA
47 cancer-associated retinopathy 30.6 VEGFA PGF FLT1
48 diabetic neuropathy 30.6 VEGFA INS ICAM1 ACE
49 hypertensive retinopathy 30.5 VEGFA FANCG ALB ACE
50 neovascular glaucoma 30.5 VEGFB VEGFA PGF KDR FLT1 CXCL8

Graphical network of the top 20 diseases related to Macular Retinal Edema:



Diseases related to Macular Retinal Edema

Symptoms & Phenotypes for Macular Retinal Edema

UMLS symptoms related to Macular Retinal Edema:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Retinal Edema:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 ACE ALB CRB1 FLT1 ICAM1 IL6
2 cellular MP:0005384 10.26 ALB CRB1 FANCC FANCG FLT1 ICAM1
3 homeostasis/metabolism MP:0005376 10.25 ACE ALB CRB1 FLT1 ICAM1 IL6
4 endocrine/exocrine gland MP:0005379 10.21 ACE ALB CRB1 FANCC FANCG ICAM1
5 immune system MP:0005387 10.21 ACE ALB CCL2 CRB1 FANCC FLT1
6 digestive/alimentary MP:0005381 10.06 ALB ICAM1 IL6 INS KCNMA1 OCLN
7 liver/biliary system MP:0005370 9.97 ACE ALB FANCC IL6 INS KDR
8 muscle MP:0005369 9.96 ALB FLT1 ICAM1 IL6 INS KCNMA1
9 neoplasm MP:0002006 9.7 ACE ALB ICAM1 IL6 PGF TNF
10 reproductive system MP:0005389 9.7 ACE FANCC FANCG FLT1 IL6 INS
11 vision/eye MP:0005391 9.32 CRB1 FLT1 ICAM1 IL6 INS KDR

Drugs & Therapeutics for Macular Retinal Edema

Drugs for Macular Retinal Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 319)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
6
Homatropine Approved Phase 4 87-00-3
7
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
8
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
9
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
10
Bromfenac Approved Phase 4 91714-94-2 60726
11
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Povidone-iodine Approved Phase 4 25655-41-8
14
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
15
Povidone Approved Phase 4 9003-39-8
16
Travoprost Approved Phase 4 157283-68-6 5282226
17
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
18
Interferon beta-1b Approved Phase 4 145155-23-3
19
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
20
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
21
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
22
Difluprednate Approved Phase 4 23674-86-4 443936
23
Verteporfin Approved, Investigational Phase 4 129497-78-5
24
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
25
Ofloxacin Approved Phase 4 82419-36-1 4583
26
Phenylephrine Approved Phase 4 59-42-7 6041
27
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
28
Metformin Approved Phase 4 657-24-9 14219 4091
29
Liraglutide Approved Phase 4 204656-20-2 44147092
30
Glucagon Approved Phase 4 16941-32-5
31
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
32
Fenofibrate Approved Phase 4 49562-28-9 3339
33
Dipivefrin Approved Phase 4 52365-63-6 3105
34
Simvastatin Approved Phase 4 79902-63-9 54454
35
leucovorin Approved Phase 4 58-05-9 6006 143
36
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
37
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
38
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
39
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
40
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
41 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43
Empagliflozin Approved Phase 4 864070-44-0
44
Glimepiride Approved Phase 4 93479-97-1 3476
45
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
48
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
49
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
50 Anticonvulsants Phase 4

Interventional clinical trials:

(show top 50) (show all 953)
# Name Status NCT ID Phase Drugs
1 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
2 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
3 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
4 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
5 The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor Unknown status NCT03475407 Phase 4 Ozurdex intravitreal injection
6 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
7 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
8 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
9 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
10 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
11 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
12 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
13 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
14 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
15 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
16 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
17 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
18 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
19 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
20 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
21 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
22 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
23 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
24 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
25 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
26 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
27 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
28 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema. Completed NCT01257815 Phase 4 Ranibizumab
29 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
30 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
31 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
32 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
33 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
34 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
35 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
36 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
37 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
38 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
39 An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice Completed NCT01315275 Phase 4 Ranibizumab
40 A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
41 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
42 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
43 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
44 Central Macular Thickness, Macular Electroretinogram, and Visual Acuity in Patients With Diabetic Macular Edema After Intravitreal Aflibercept Injection. A One Month Pre-Post Intervention Follow Up Study Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
45 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
46 A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
47 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
48 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
49 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
50 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4 Bromfenac;Ketorolac;Diclofenac

Search NIH Clinical Center for Macular Retinal Edema

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Flurbiprofen
Flurbiprofen sodium

Genetic Tests for Macular Retinal Edema

Anatomical Context for Macular Retinal Edema

MalaCards organs/tissues related to Macular Retinal Edema:

40
Eye, Endothelial, Retina, Testes, Bone, Kidney, Brain

Publications for Macular Retinal Edema

Articles related to Macular Retinal Edema:

(show top 50) (show all 9652)
# Title Authors PMID Year
1
Scleral fixation of fluocinolone acetonide implant. 61
32577584 2020
2
Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management. 61
32092363 2020
3
Anti-inflammatory Medication of Cataract Surgery in Pseudoexfoliation Syndrome - NSAID Is Needed. 61
31801388 2020
4
A RANDOMIZED PAIRED-EYE TRIAL OF INTRAVITREAL DEXAMETHASONE IMPLANT FOR CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA. 61
31166248 2020
5
Fundamental principles of an effective diabetic retinopathy screening program. 61
32222818 2020
6
Microcystic Macular Edema in Optic Nerve Glioma. 61
32564817 2020
7
Feelings, preoperative anxiety, and need for information in patients undergoing intravitreal injections. 61
32346786 2020
8
Cost-Effectiveness of Preoperative OCT in Cataract Evaluation for Multifocal Intraocular Lens. 61
32173111 2020
9
NONCONFOCAL ULTRA-WIDEFIELD SCANNING LASER OPHTHALMOSCOPY: Polarization Artifacts and Diabetic Macular Edema. 61
31181039 2020
10
Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management. 61
32209341 2020
11
Real-world Outcomes among Eyes with Center-Involving Diabetic Macular Edema and Good Visual Acuity. 61
31829753 2020
12
Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia. 61
32114640 2020
13
Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. 61
32173113 2020
14
ETIOLOGY AND CLINICAL CHARACTERISTICS OF MACULAR EDEMA IN PATIENTS WITH FAMILIAL EXUDATIVE VITREORETINOPATHY. 61
31404032 2020
15
Effect of Iris Color on the Outcome of Descemet Membrane Endothelial Keratoplasty. 61
32195753 2020
16
Unintentional injection of a dexamethasone implant into the crystalline lens: a case report. 61
32490978 2020
17
Safety and efficacy of custom foldable silicone artificial iris implantation: prospective compassionate-use case series. 61
32176161 2020
18
Atypical perifoveal exudative vascular anomalous complex (PEVAC) with multifocal and bilateral presentation. 61
32368691 2020
19
Successful management of persistent macular hole after macular hole surgery with intravitreal triamcinolone acetonide: A case report. 61
32461478 2020
20
A Novelty Route for Smartphone-based Artificial Intelligence Approach to Ophthalmic Screening. 61
32520771 2020
21
Cystoid macular edema precipitated by altitude in a patient with X-linked retinitis pigmentosa. 61
32400255 2020
22
Optical coherence tomography in the evaluation of retinitis pigmentosa. 61
32552399 2020
23
Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy. 61
32190783 2020
24
Two-year results of intravitreal injections of aflibercept in Coats' Disease; a case report. 61
32541440 2020
25
Intraocular Lens Implantation in the Absence of Zonular Support: An Outcomes and Safety Update: A Report by the American Academy of Ophthalmology. 61
32507620 2020
26
Incidence of macular edema development after filtration surgery. 61
32055953 2020
27
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial. 61
32107188 2020
28
Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial. 61
32560639 2020
29
The role of serum inflammation-based factors in Anti-VEGF treatment for macular edema secondary to retinal vein occlusion and its subtypes. 61
32506058 2020
30
PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial. 61
31157710 2020
31
Spectral domain optical coherence tomography classification of diabetic macular edema: a new proposal to clinical practice. 61
32152718 2020
32
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy. 61
32356244 2020
33
Statin reduces the incidence of diabetic retinopathy and its need for intervention: A systematic review and meta-analysis. 61
32530705 2020
34
THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA. 61
30897067 2020
35
Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch. 61
32493065 2020
36
Response to: Comments to: Management of diabetic macular edema patients in clinical practice in Spain. 61
32515604 2020
37
Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema. 61
32245883 2020
38
Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema. 61
31885209 2020
39
Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema. 61
32267790 2020
40
COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT. 61
30950970 2020
41
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. 61
31567817 2020
42
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. 61
32157555 2020
43
Postoperative complications in Medicare beneficiaries following endothelial keratoplasty (EK) surgery. 61
32574781 2020
44
Joint Diabetic Macular Edema Segmentation and Characterization in OCT Images. 61
32562127 2020
45
Spontaneous late reopening of a successfully operated and closed full-thickness macular hole. 61
32195442 2020
46
Long-term results of aphakia management by scleral fixation intraocular lens placement with knotless transscleral Z-suture method. 61
32067152 2020
47
Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. 61
31570814 2020
48
[Pseudophakic cystoid macular edema]. 61
32468102 2020
49
Pentosan polysulfate sodium-induced pigmentary maculopathy with non-leaking cystoid macular edema successfully treated with anti-VEGF therapy. 61
32541441 2020
50
Effect of intracameral phenylephrine 1.0%-ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. 61
32541407 2020

Variations for Macular Retinal Edema

Expression for Macular Retinal Edema

Search GEO for disease gene expression data for Macular Retinal Edema.

Pathways for Macular Retinal Edema

Pathways related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFB VEGFA TNF PGF KDR IL6
2
Show member pathways
13.42 VEGFB TNF PGF KDR IL6 FLT1
3
Show member pathways
13.42 VEGFB VEGFA TNF PGF KDR INS
4
Show member pathways
13.3 VEGFB TNF PGF KDR IL6 FLT1
5
Show member pathways
13.29 VEGFB VEGFA TNF PGF KDR IL6
6
Show member pathways
13.07 TNF OCLN IL6 CXCL8 CCL2 ACE
7
Show member pathways
13.05 VEGFB PGF KDR INS IL6 FLT1
8
Show member pathways
12.96 VEGFB VEGFA TNF PGF KDR INS
9
Show member pathways
12.95 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
10
Show member pathways
12.87 VEGFA TNF INS IL6 ICAM1 CXCL8
11
Show member pathways
12.83 TNF IL6 ICAM1 CXCL8 CCL2
12 12.76 VEGFB VEGFA TNF PGF KDR INS
13
Show member pathways
12.75 VEGFB VEGFA PGF KDR INS FLT1
14
Show member pathways
12.71 VEGFB TNF PGF KDR IL6 FLT1
15
Show member pathways
12.67 VEGFA OCLN KDR ICAM1 CCL2
16
Show member pathways
12.43 VEGFB VEGFA PGF KDR FLT1
17
Show member pathways
12.41 VEGFA KDR ICAM1 CCL2
18
Show member pathways
12.41 VEGFB PGF KDR IL6 FLT1
19
Show member pathways
12.34 TNF IL6 CXCL8 CCL2
20
Show member pathways
12.34 TNF IL6 CXCL8 CCL2
21
Show member pathways
12.32 TNF INS IL6 ICAM1 CCL2 ALB
22 12.29 TNF OCLN IL6 CXCL8
23 12.25 TNF IL6 CXCL8 CCL2
24
Show member pathways
12.23 VEGFB TNF PGF KDR IL6 FLT1
25 12.19 VEGFA TNF IL6 CXCL8
26 12.12 VEGFA TNF KDR ICAM1 CCL2
27 12.1 VEGFA KDR INS IL6 ALB
28 12.03 TNF IL6 CXCL8 CCL2
29 12.01 TNF IL6 ICAM1 CXCL8 CCL2
30 11.99 TNF IL6 ICAM1 CCL2
31 11.98 VEGFA INS IL6 FLT1
32 11.87 VEGFB KDR FLT1 CCL2
33
Show member pathways
11.86 VEGFB VEGFA PGF KDR FLT1
34 11.81 IL6 ICAM1 CXCL8
35 11.79 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
36 11.77 TNF IL6 CXCL8
37 11.69 TNF IL6 CXCL8 CCL2
38 11.63 TNF IL6 CXCL8
39
Show member pathways
11.63 VEGFA TNF IL6 ICAM1 CXCL8
40 11.61 INS IL6 CXCL8
41 11.57 VEGFA IL6 CXCL8
42 11.54 VEGFA INS IL6
43 11.54 TNF IL6 ICAM1
44 11.5 VEGFB VEGFA TNF IL6 ICAM1 CXCL8
45 11.49 VEGFB VEGFA KDR FLT1
46
Show member pathways
11.47 VEGFA KDR INS
47 11.47 TNF IL6 ICAM1 CXCL8 CCL2
48 11.41 TNF IL6 ICAM1
49 11.41 TNF IL6 ICAM1 CXCL8 CCL2
50 11.37 IL6 CXCL8 CCL2

GO Terms for Macular Retinal Edema

Cellular components related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 VEGFB VEGFA TNF PGF KDR INS
2 extracellular space GO:0005615 9.4 VEGFB VEGFA TNF PGF INS IL6
3 platelet alpha granule lumen GO:0031093 9.33 VEGFB VEGFA ALB

Biological processes related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.07 VEGFA TNF OCLN INS IL6
2 positive regulation of cell proliferation GO:0008284 10.04 VEGFA PGF KDR INS IL6 FLT1
3 negative regulation of gene expression GO:0010629 9.97 VEGFA TNF OCLN KDR ACE
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF KDR ICAM1 CCL2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF INS IL6 ICAM1
6 regulation of cell shape GO:0008360 9.92 VEGFA KDR ICAM1 CCL2
7 positive regulation of protein phosphorylation GO:0001934 9.92 VEGFB VEGFA TNF PGF KDR
8 cytokine-mediated signaling pathway GO:0019221 9.91 VEGFA TNF IL6 ICAM1 CXCL8 CCL2
9 cellular response to tumor necrosis factor GO:0071356 9.89 OCLN ICAM1 CXCL8 CCL2
10 cellular response to lipopolysaccharide GO:0071222 9.89 TNF IL6 ICAM1 CXCL8 CCL2
11 positive regulation of MAPK cascade GO:0043410 9.85 KDR INS IL6 FLT1
12 response to hypoxia GO:0001666 9.85 VEGFB VEGFA PGF KCNMA1 ICAM1
13 positive regulation of angiogenesis GO:0045766 9.85 VEGFB VEGFA PGF KDR FLT1 CXCL8
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 VEGFA TNF IL6
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 TNF KDR INS FLT1
16 positive regulation of MAP kinase activity GO:0043406 9.83 VEGFA TNF FLT1
17 humoral immune response GO:0006959 9.82 TNF IL6 CCL2
18 positive chemotaxis GO:0050918 9.82 VEGFB VEGFA PGF
19 positive regulation of endothelial cell proliferation GO:0001938 9.81 VEGFB VEGFA PGF KDR
20 angiogenesis GO:0001525 9.8 VEGFB VEGFA PGF KDR FLT1 CXCL8
21 positive regulation of cell division GO:0051781 9.79 VEGFB VEGFA PGF
22 monocyte chemotaxis GO:0002548 9.79 IL6 FLT1 CCL2
23 ovarian follicle development GO:0001541 9.78 VEGFA ICAM1 FANCG
24 protein kinase B signaling GO:0043491 9.76 TNF KDR CCL2
25 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.73 VEGFA KDR FLT1
26 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.72 VEGFB VEGFA PGF KDR FLT1
27 negative regulation of lipid storage GO:0010888 9.67 TNF IL6
28 vascular wound healing GO:0061042 9.66 VEGFA KDR
29 neutrophil mediated immunity GO:0002446 9.65 IL6 ACE
30 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 TNF IL6 ICAM1
31 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.64 VEGFA KDR
32 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.63 VEGFA KDR
33 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.6 VEGFA ACE
34 positive regulation of mast cell chemotaxis GO:0060754 9.58 VEGFB VEGFA PGF
35 induction of positive chemotaxis GO:0050930 9.46 VEGFB VEGFA PGF CXCL8
36 sprouting angiogenesis GO:0002040 9.35 VEGFB VEGFA PGF KDR FLT1
37 vascular endothelial growth factor signaling pathway GO:0038084 9.02 VEGFB VEGFA PGF KDR FLT1

Molecular functions related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 VEGFB VEGFA TNF PGF OCLN MRAP
2 growth factor activity GO:0008083 9.71 VEGFB VEGFA PGF IL6
3 identical protein binding GO:0042802 9.61 VEGFB VEGFA TNF PGF MRAP KDR
4 cytokine activity GO:0005125 9.55 VEGFA TNF IL6 CXCL8 CCL2
5 chemoattractant activity GO:0042056 9.54 VEGFB VEGFA PGF
6 vascular endothelial growth factor binding GO:0038085 9.46 KDR FLT1
7 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 KDR FLT1
8 vascular endothelial growth factor receptor 1 binding GO:0043183 9.32 VEGFB VEGFA
9 vascular endothelial growth factor receptor binding GO:0005172 8.8 VEGFB VEGFA PGF

Sources for Macular Retinal Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....